UK markets open in 1 hour 58 minutes
  • NIKKEI 225

    29,630.35
    -209.36 (-0.70%)
     
  • HANG SENG

    24,221.54
    +122.40 (+0.51%)
     
  • CRUDE OIL

    70.51
    -0.05 (-0.07%)
     
  • GOLD FUTURES

    1,776.70
    -1.50 (-0.08%)
     
  • DOW

    33,919.84
    -50.63 (-0.15%)
     
  • BTC-GBP

    30,697.24
    -532.90 (-1.71%)
     
  • CMC Crypto 200

    1,036.80
    -27.05 (-2.54%)
     
  • ^IXIC

    14,746.40
    +32.49 (+0.22%)
     
  • ^FTAS

    4,029.01
    +42.11 (+1.06%)
     

Global $136 Billion Active Pharmaceutical Ingredients CDMO Market to 2026 - Patent Expirations and Rise in Demand for Generic Drugs and Biologic Innovation

·4-min read

Dublin, July 29, 2021 (GLOBE NEWSWIRE) -- The "Active Pharmaceutical Ingredients CDMO Market Size, Share & Trends Analysis Report by Product (Highly Potent API, Antibody Drug Conjugate), by Synthesis, by Drugs, by Application, by Workflow, by Region and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.

The global active pharmaceutical ingredients CDMO market size is expected to reach USD 136.1 billion by 2028. The market is expected to expand at a CAGR of 6.7% from 2021 to 2028.

The increasing pharmaceutical R&D investment, patent expirations and rise in demand for generic drugs and biologic innovation are the factors driving the market.

The growth of small molecules, rising Active Pharmaceutical Ingredient (API) complexity and the need to reduce costs are factors contributing to the rapid expansion of outsourcing services in the pharmaceutical sector. Only a few companies have achieved global reach and scale in the Contract Development and Manufacturing Organization (CDMO) sector, which is still fragmented. Besides, many companies are providing one-stop-shop solutions as an integrated source of APIs and formulations.

However, due to the COVID-19 pandemic, governments worldwide have opted to boycott APIs made in China. Due to government-imposed lockdown limitations in China, 44 firms were declared non-operational during the pandemic. As a consequence, various countries have launched programs to develop their own APIs and countries across the EU have re-evaluated their healthcare models in order to combat the virus and ensure a steady supply of APIs.

COVID-19 has placed unprecedented expectations on API makers, as evidenced by the substantial increase in demand for medications required to manage critically ill patients on mechanical ventilation. As a result, the sudden need to rapidly increase production has emphasized the need for adaptability for API CDMOs in maintaining drug supply, with some companies proving better able to withstand the pressures of quick scale up than others.

Active Pharmaceutical Ingredients CDMO Market Report Highlights

  • The traditional active pharmaceutical ingredient dominated the market and accounted for the largest revenue share of 40.5% in 2020

  • The innovative drugs segment held 74.6% of the revenue share in 2020. This is largely attributed due to increasing FDA approvals for new molecular entities and the increased focus on R&D by innovator API companies

  • The oncology segment dominated the market and accounted for the largest revenue share of 35.1% in 2020. This is due to the increasing demand for highly active APIs for cancer therapy

  • In Asia Pacific, the market is expected to register the fastest growth rate of 8.9% over the forecast period. Due to the extreme rising number of pharmaceutical companies and contract manufacturing organizations in developing countries like India and China, Asia Pacific is likely to overtake Europe and North America in the near future

Key Topics Covered:

Chapter 1 Methodology and Scope

Chapter 2 Executive Summary

Chapter 3 Active Pharmaceutical Ingredient CDMO Market: Variables, Trends, & Scope
3.1 Market Segmentation and Scope
3.2 Market Dynamics
3.2.1 Market Driver Analysis
3.2.1.1 Increasing pharmaceutical R&D investment
3.2.1.2 Rising demand for generic drugs
3.2.1.3 Patent expiration
3.2.1.4 Expanding consumption of biopharmaceuticals
3.2.2 Market Restraint Analysis
3.2.2.1 Stringent government regulations
3.3 Penetration & Growth Prospect Mapping
3.4 COVID-19 Impact on the Market
3.5 Major Deals and Strategic Alliances Analysis
3.6 Active Pharmaceutical Ingredient CDMO: Market Analysis Tools
3.6.1 Industry Analysis - Porter's
3.6.2 PESTEL Analysis

Chapter 4 Active Pharmaceutical Ingredient CDMO Market: Product Segment Analysis
4.1 Active Pharmaceutical Ingredient CDMO Market: Product Market Share Analysis, 2020 & 2028
4.2 Traditional Active Pharmaceutical Ingredient
4.2.1 Traditional Active Pharmaceutical Ingredient Market, 2016 - 2028 (USD Million)
4.3 Highly Potent Active Pharmaceutical Ingredient
4.4 Antibody Drug Conjugate

Chapter 5 Active Pharmaceutical Ingredient CDMO Market: Synthesis Segment Analysis
5.1 Active Pharmaceutical Ingredient CDMO Market: Synthesis Market Share Analysis, 2020 & 2028
5.2 Synthetic
5.3 Biotech

Chapter 6 Active Pharmaceutical Ingredient CDMO Market: Drug Segment Analysis
6.1 Active Pharmaceutical Ingredient CDMO Market: Drug Market Share Analysis, 2020 & 2028
6.2 Innovative
6.3 Generics

Chapter 7 Active Pharmaceutical Ingredient CDMO Market: Application Segment Analysis
7.1 Active Pharmaceutical Ingredient CDMO Market: Application Market Share Analysis, 2020 & 2028
7.2 Oncology
7.3 Hormonal
7.4 Glaucoma
7.5 Cardiovascular
7.6 Diabetes

Chapter 8 Active Pharmaceutical Ingredient CDMO Market: Work Flow Segment Analysis
8.1 Active Pharmaceutical Ingredient CDMO Market: Workflow Market Share Analysis, 2020 & 2028
8.2 Clinical
8.3 Commercial

Chapter 9 Active Pharmaceutical Ingredient CDMO Market: Regional Analysis

Chapter 10 Company Profiles
10.1 Company Overview
10.2 Service Benchmarking
10.3 Financial Performance
10.4 Strategic Initiatives

  • Cambrex

  • ReciPharm

  • ThermoFisher Pantheon

  • Corden Pharma.

  • Samsung Biologics

  • Lonza

  • Catalent

  • Siegfried

  • Piramal Pharma Solutions

  • Boehringer Ingelheim

For more information about this report visit https://www.researchandmarkets.com/r/wlflb5

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting